PDCD1 and rectal cancer: For rectal cancer, a study of dostarlimab (a PD-1 blocker) given to 12 patients with dMMR locally advanced rectal cancer [7] demonstrated a 100% clinical response rate at 12 months follow-up [7], assuring an organ-sparing strategy in all patients, although long-term data are awaited.